GNS Healthcare applies artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.

Insilico Medicine develops a range of generative adversarial networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions that transform the way innovative medicines and treatments are discovered and accelerate research and development. The company was founded in 2014 and is based in Hong Kong.

Cyclica is a global biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica's structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.

BERG is a Boston-based biopharma company focused on taking a bold "back to biology" approach to therapeutic discovery using its unique AI-based Interrogative Biology platform. This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient's own biology drives the platform's results and guides the company in the discovery and development of drugs, diagnostics and healthcare applications. Its platform utilizes patient population health data to bring actionable Patient Intelligence to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.